• SKIP TO CONTENT
  • SKIP NAVIGATION
  • Patient Resources
    • COVID-19 Patient Resource Center
    • Clinical Trials
    • Search Clinical Trials
    • Patient Notification System
    • What is Clinical Research?
    • Volunteering for a Clinical Trial
    • Understanding Informed Consent
    • Useful Resources
    • FDA Approved Drugs
  • Professional Resources
    • Research Center Profiles
    • Clinical Trial Listings
    • Market Research
    • FDA Approved Drugs
    • Training Guides
    • Books
    • eLearning
    • Events
    • Newsletters
    • White Papers
    • SOPs
    • eCFR and Guidances
  • White Papers
  • Trial Listings
  • Advertise
  • COVID-19
  • iConnect
  • Sign In
  • Create Account
  • Sign Out
  • My Account
Home » Nordic Capital buys ERT from Genstar Capital

Nordic Capital buys ERT from Genstar Capital

March 14, 2016
CenterWatch Staff

Genstar Capital, a private equity firm focused on the healthcare, software, financial services and industrial technology industries, has announced the sale of ERT, a provider of high-quality patient data collection solutions for use in clinical drug development, to Nordic Capital Fund VIII.

Genstar acquired ERT in 2012 for approximately $400 million in a take-private transaction.  Since then, Genstar's investment professionals implemented significant enhancements to reposition the business, accelerate growth, and build a world-class management team. Genstar invested resources and capital in ERT, including the acquisitions of invivodata, eClinical Insights and PHT,  that complemented substantial internal investments in people and technology to create the most comprehensive solution for patient endpoint collection and analytics for global clinical trials.

"ERT was a strong company when we acquired it, yet to make it even stronger we built upon its robust internal software and data capabilities and successfully completed three transformative acquisitions," said Roman Margolin, principal of Genstar. "We also were able to recruit a number of exceptional leaders to the company, including Jim Corrigan as CEO. Combined with meaningful growth initiatives developed in concert with Jim and his management team, sales for ERT were dramatically enhanced and the company is extremely well positioned to continue as a trusted partner to a diverse customer base of top pharma and biotech companies and major CROs."

Corrigan, CEO of ERT, said, "Genstar had a deep understanding of ERT's markets, mission, and value, and their strategic guidance contributed greatly to our ongoing growth and development.  As a result, we are better positioned to continue improving the productivity of the drug development process, reduce the risk of failure and innovate better health. ERT has supported over 50% of all new drug approvals in the past three years and we remain committed to providing solutions which are transformational and will benefit the global studies in which we are involved."

Jean-Pierre L. Conte, chairman and managing director of Genstar, said, "First of all, I want to thank ERT's CEO Jim Corriganand the entire management team for their tireless hard work in achieving this result. We are very pleased with the successful outcome of this investment which was achieved in large part by our ability to drive change in a sector in which we have deep industry expertise. In the most competitive private equity environment ever, Genstar's investment strategy continues to produce superior returns. Going forward, we remain committed to the healthcare sector where we see exciting opportunities to apply change initiatives that create industry leaders."

The transaction is subject to customary regulatory and closing approvals and is expected to be completed in the second quarter.

Upcoming Events

  • 16Feb

    Fundamentals of FDA Inspection Management: Reduce Anxiety, Increase Inspection Success

  • 21May

    WCG MAGI Clinical Research Conference – 2023 East

Featured Products

  • Spreadsheet Validation: Tools and Techniques to Make Data in Excel Compliant

    Spreadsheet Validation: Tools and Techniques to Make Data in Excel Compliant

  • Surviving an FDA GCP Inspection

    Surviving an FDA GCP Inspection: Resources for Investigators, Sponsors, CROs and IRBs

Featured Stories

  • Revamp-360x240.png

    Califf Calls for Major Evidence Generation Revamp, Experts’ Opinions Differ

  • AskTheExpertsGreen-360x240.png

    Ask the Experts: Managing Investigational Products

  • SurveywBlueBackground-360x240.png

    Survey Outlines Site Challenges, Successes on Diversity

  • PatientCentricity-360x240.png

    Site Spotlight: DM Clinical Shows Patient Centricity Doesn’t Have to Break the Bank

Standard Operating Procedures for Risk-Based Monitoring of Clinical Trials

The information you need to adapt your monitoring plan to changing times.

Learn More Here
  • About Us
  • Contact Us
  • Privacy Policy
  • Do Not Sell or Share My Data

Footer Logo

300 N. Washington St., Suite 200, Falls Church, VA 22046, USA

Phone 617.948.5100 – Toll free 866.219.3440

Copyright © 2023. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing